Bioventus (NASDAQ:BVS) Stock Rating Upgraded by Cantor Fitzgerald

Bioventus (NASDAQ:BVSGet Free Report) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities analysts also recently issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Barrington Research upgraded Bioventus to a “strong-buy” rating in a research report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy”.

Get Our Latest Stock Analysis on Bioventus

Bioventus Stock Performance

Shares of BVS opened at $9.10 on Wednesday. The firm has a fifty day moving average of $8.10 and a 200-day moving average of $7.49. The company has a market cap of $753.12 million, a price-to-earnings ratio of 75.84 and a beta of 0.78. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.14 and a current ratio of 1.74. Bioventus has a 1 year low of $5.81 and a 1 year high of $11.25.

Bioventus (NASDAQ:BVSGet Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter. The firm had revenue of $157.90 million for the quarter. Bioventus had a net margin of 1.39% and a return on equity of 26.38%.

About Bioventus

(Get Free Report)

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

See Also

Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.